HC Wainwright Reaffirms "Buy" Rating for Vor Biopharma (NYSE:VOR)

Key Points

• Vor Biopharma has received a "buy" rating from HC Wainwright, with a price target of $3.00, indicating a potential upside of 48.51% from its previous close.
• Recently, other analysts have downgraded Vor Biopharma from "strong-buy" to "hold," but the overall consensus rating remains a "Moderate Buy" with a target price of $5.63.
• Institutional investors own 97.29% of Vor Biopharma's stock, with significant recent purchases from firms like Goldman Sachs Group Inc. and Money Concepts Capital Corp.

Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $3.00 price objective on the stock. HC Wainwright's price target indicates a potential upside of 50.38% from the company's current price. HC Wainwright also issued estimates for Vor Biopharma's FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.21 EPS.

A number of other brokerages also recently weighed in on VOR. Baird R W downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Jones Trading downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. JMP Securities restated a "market perform" rating and set a $6.00 price objective on shares of Vor Biopharma in a research note on Friday, May 9th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Finally, Citizens Jmp downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 9th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Vor Biopharma currently has a consensus rating of "Moderate Buy" and an average price target of $6.07.

Vor Biopharma Trading Down 2.2%

VOR stock traded down $0.0450 during midday trading on Thursday, hitting $1.9950. 1,255,576 shares of the company's stock were exchanged, compared to its average volume of 7,960,814. Vor Biopharma has a 12-month low of $0.13 and a 12-month high of $3.29. The firm has a 50 day moving average price of $1.62 and a 200-day moving average price of $1.04. The stock has a market capitalization of $252.73 million, a price-to-earnings ratio of -1.21 and a beta of 2.06.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VOR. RA Capital Management L.P. increased its position in Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in Vor Biopharma in the 4th quarter worth about $707,000. Jane Street Group LLC bought a new position in shares of Vor Biopharma in the 1st quarter valued at approximately $140,000. OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma in the 1st quarter valued at approximately $100,000. Finally, Trustees of Columbia University in the City of New York bought a new position in shares of Vor Biopharma in the 4th quarter valued at approximately $102,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.